Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individualresults may vary – nothing you hear on this podcast should be considered medical advice. All claims are supportedby clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 UserGuide. For product-related questions, please refer to the instructions for use. For complete safety information, goto dexcom.com/safety-information.Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucosemonitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has nolimitations for use in pregnancy.About New Expanded Medicare GuidelinesAbout Hello DexcomDexcom Provider websiteAbout Medicaid coverageDexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Usersshould confirm data and connections with their collaborator devices and products.A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends.CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatmentdecisions.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and itscomponents according to the instructions for use provided with your device and available athttps://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings,precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low bloodglucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result ininjury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to makediabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medicalemergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals toassist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historicalCGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGMdevices with data interface capabilities. Caution: The software does not provide any medical advice and should notbe used for that purpose. Home users must consult a healthcare professional before making any medicalinterpretation and therapy adjustments from the information in the software. Caution: Healthcare professionalsshould use information in the software in conjunction with other clinical information available to them. Caution:Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S.,and may be registered in other countries.References1. Dexcom G7 User Guide2. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control inPatients With Type 2 Diabetes Treated With Basal Insulin: A Randomized ClinicalTrial. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.74443. Aleppo G, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304